Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Andrew Koren"'
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 11, Iss 3 (2022)
Background Atrial tachyarrhythmias are common after atrial fibrillation ablation, so adjunctive antiarrhythmic drug therapy is often used. Data on the effectiveness and safety of dronedarone and sotalol after AF ablation are limited. Here, we compare
Externí odkaz:
https://doaj.org/article/dc8e6e937419467e8de30dd575f7aa96
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 10, Iss 6 (2021)
Background Current American Heart Association/American College of Cardiology/Heart Rhythm Society guidelines and European Society of Cardiology guidelines recommend antiarrhythmic drugs (AADs) for maintenance of sinus rhythm in patients with atrial f
Externí odkaz:
https://doaj.org/article/3968cc03398f4f4ab45735d14785c551
Autor:
Ying Xian, Ann Marie Navar, Shuang Li, Zhuokai Li, Jennifer Robinson, Salim S. Virani, Michael J. Louie, Andrew Koren, Anne Goldberg, Veronique L. Roger, Peter W. F. Wilson, Eric D. Peterson, Tracy Y. Wang
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 8, Iss 19 (2019)
Background Current treatment guidelines strongly recommend statin therapy for secondary prevention. However, it remains unclear whether patients’ perceptions of cardiovascular risk, beliefs on cholesterol, or the intensity of prescribed statin ther
Externí odkaz:
https://doaj.org/article/a0053e3dd28c4b249aead6317e1d9a3c
Autor:
Valérie Corp dit Genti, Nassir F. Marrouche, Carina Blomström-Lundqvist, Mattias Wieloch, Stuart J. Connolly, Stefan H. Hohnloser, Andrew Koren
Publikováno v:
Clinical Cardiology
Background: Atrial fibrillation/atrial flutter (AF/AFL) burden increases with increasing duration of AF/AFL history. Hypothesis: Outcomes with dronedarone may also be impacted by duration of AF/AFL history. Methods: In this post hoc analysis of ATHEN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e021468fb899b14071d72a26d57ffa2
https://doi.org/10.1002/clc.23463
https://doi.org/10.1002/clc.23463
Autor:
Andrew C.T. Ha, Andrew Koren, John D. Stewart, Denis Roy, Paul Dorian, George J. Klein, Stuart J. Connolly
Publikováno v:
American Heart Journal. 226:152-160
It is assumed that electrical cardioversion (ECV) improves the quality of life (QoL) of patients with atrial fibrillation (AF) by restoring sinus rhythm (SR).We examined the effect of ECV and rhythm status on QoL of patients with symptomatic persiste
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a710bb72dda5c0d9e87c8e46b35f0ae7
https://doi.org/10.1016/j.ahj.2020.05.004
https://doi.org/10.1016/j.ahj.2020.05.004
Autor:
Matthew K. Ito, Sergio Fazio, Andrew Koren, Jessica Minnier, Michael D. Shapiro, Ivy W. Kam, Tahir Mahmood, Qian H Li
Publikováno v:
European Journal of Preventive Cardiology. 28:816-822
AimsProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors consistently reduce low-density lipoprotein cholesterol (LDL-C) by 50–60% and lipoprotein(a) (Lp(a)) by 20–30%, but the mechanism of Lp(a) lowering remains unclear. If Lp(a) is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::774dc03165e7045d563e040023d20a01
https://doi.org/10.1177/2047487320915803
https://doi.org/10.1177/2047487320915803
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Current American Heart Association/American College of Cardiology/Heart Rhythm Society guidelines and European Society of Cardiology guidelines recommend antiarrhythmic drugs (AADs) for maintenance of sinus rhythm in patients with atrial f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f26c06dfcffc281046795d06db40f1a8
https://doi.org/10.1161/jaha.120.016792
https://doi.org/10.1161/jaha.120.016792
Autor:
Roger Echols, Tsutae Den Nagata, Andrew Koren, Christopher Longshaw, Yoshinori Yamano, Matteo Bassetti, Andreas Karas
Publikováno v:
The Lancet Infectious Diseases. 21:908-909
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::26e736032284125b00114069677e8cb8
https://doi.org/10.1016/s1473-3099(21)00328-5
https://doi.org/10.1016/s1473-3099(21)00328-5
Autor:
Om P. Ganda, Lawrence A. Leiter, Jorge Plutzky, Santosh K. Sanganalmath, Maja Bujas-Bobanovic, Alexia Letierce, Jonas Mandel, Andrew Koren
Publikováno v:
Diabetes, Obesity & Metabolism
Aims Individuals with both diabetes mellitus (DM) and atherosclerotic cardiovascular disease (ASCVD) are at very high risk of cardiovascular events. This post‐hoc analysis evaluated efficacy and safety of the PCSK9 inhibitor alirocumab among 984 in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cec65022ad60677478520b22de8b81e1
https://doi.org/10.1111/dom.13384
https://doi.org/10.1111/dom.13384
Autor:
James M. McKenney, Louis Kantaros, John Stewart, Charles J. Glueck, Anne C. Goldberg, Joseph Elassal, Andrew Koren, Alan S. Brown
Publikováno v:
Journal of Clinical Lipidology. 12:662-668
Background The alirocumab expanded use program provided open-label access to alirocumab before its commercial availability to patients with severe hypercholesterolemia not controlled with maximally tolerated doses of standard-of-care lipid-lowering t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d250a6e550526a6d62f4e094b5e90b0
https://doi.org/10.1016/j.jacl.2018.01.013
https://doi.org/10.1016/j.jacl.2018.01.013